AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 111 min read$VNRX

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE American: VNRX) scheduled a conference call for Aug. 14, 2026 at 8:30 a.m. ET to discuss its Q2 2026 financial and operating results and provide a business update. The call will be hosted by company executives and include a live webcast and a replay until Aug. 28, 2026.

Original reporting
prnewswire.com
Published Aug 11, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update — source image
Source · prnewswire.com
Decision brief

The 30-second read

$VNRXNeutralMed
01

Why it matters

The only actionable element in the text is the scheduled call date/time and replay availability; any price impact will come from the earnings and business update content delivered on Aug. 14.

02

Market read

This PR is a calendar catalyst for VNRX, but it contains no new financial figures or guidance changes.

03

What to watch

Traders should focus on whether management provides updated timelines for epigenetics blood tests, NETosis/sepsis monitoring progress, and any changes to commercialization or R&D cadence, none of which are specified in this PR.

Relevance 4/10Novelty 3/10Timing: Aug. 14 pre-market/into the 8:30 a.m. ET earnings call

Background

VolitionRx will host a conference call to discuss Q2 2026 financial and operating results plus a business update.

Company-level read

Ticker impact

$VNRXNeutralMedium confidence
Context

VolitionRx schedules its Q2 2026 earnings and business update call for Aug. 14, signaling an upcoming catalyst for VNRX fundamentals and guidance.

Expected impact

Likely modest pre-event volatility and a larger move only if the call includes materially different results or guidance versus expectations.

Evidence & confidence

The article provides timing and event details but no financial numbers, guidance, or new operational disclosures; impact depends entirely on what management reports on the call.

Market effects

Sector

Limited direct sector read-through because no new clinical, regulatory, or product milestone is disclosed here.

Regional

None indicated; event is company-specific.

Global

None indicated; no cross-border deal, regulator action, or macro linkage is mentioned.

Counterpoint

What could challenge this read

If the market already expects the call and consensus is stable, the stock may trade mostly on liquidity and sentiment rather than fundamentals until results are released.

Key entities

  • company
    VolitionRx Limited

    NYSE American-listed epigenetics diagnostics company scheduling its Q2 2026 earnings and business update call.

  • executive
    Cameron Reynolds

    President and Group Chief Executive Officer listed as a call participant.

  • executive
    Terig Hughes

    Group Chief Financial Officer listed as a call participant.

Read at source← All news

Related articles

AUG 26
$VNRXMedAI 8/10

Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down

VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.

rttnews.com2 min
AUG 13
$VNRXLow

VOLITIONRX LTD (VNRX): Results of Operations and Financial Condition

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit

SEC EDGAR 8-K3 min
AUG 13
$VNRXMed

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

prnewswire.com4 min
SEP 2
$MDBMedAI 8/10

MongoDB earnings analysis: questions answered and next catalysts

MongoDB (MDB) reported Q2 2027 revenue of $771.8M, beating estimates by 30% YoY, and raised FY2027 guidance to $2.99B–$3.03B. Despite strong results, shares fell 11.98% to $382.19 due to decelerating Atlas growth. Management highlighted early AI demand and strong enterprise growth but noted limited AI monetization. Investors await further catalysts, including Investor Day and Q3 earnings, to assess AI's impact on growth.

investing.com2 min